Literature DB >> 31558417

Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.

.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) are significant health burdens worldwide with a substantial rise in prevalence. Both can progress to liver cirrhosis. Recent studies have shown that the gut microbiome was associated with NAFLD/AFLD development and progression. The present review focuses on the characteristics of bacteria in NAFLD, AFLD and liver cirrhosis. The similarities and differences of intestinal bacteria are discussed. This study reviews the existing literatures on the microbiota, fatty liver disease, and liver cirrhosis based on Pubmed database. The study showed NAFLD was characterized by increased amounts of Lachnospiraceae from the phylum Firmicutes and Roseburia from the Lachnospiraceae family, and the proportion of Enterobacteria and Proteobacteria was increased after alcohol intake. Reduced Bacteroidetes was observed in cirrhosis. Microbiota can improve or aggravate the above liver diseases through several mechanisms, like increasing liver lipid metabolism, increasing alcohol production, increasing intestinal permeability, bacterial translocation, intestinal bacterial overgrowth, enteric dysbiosis, and impairing bile secretion. Different hepatic diseases owned different intestinal bacterial characters. Microbiota can improve or aggravate three kinds of liver diseases through several mechanisms. However, the depletion of these bacteria is needed to verify their role in liver disease.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Alcoholic fatty liver disease; Gut microbiome; Liver cirrhosis; Non-alcoholic fatty liver disease

Year:  2019        PMID: 31558417     DOI: 10.1016/j.aohep.2019.06.020

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  11 in total

1.  Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease.

Authors:  John P Haran; Beth A McCormick
Journal:  Gastroenterology       Date:  2020-12-08       Impact factor: 22.682

Review 2.  Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.

Authors:  Sergio Quesada-Vázquez; Gerard Aragonès; Josep M Del Bas; Xavier Escoté
Journal:  Cells       Date:  2020-01-10       Impact factor: 6.600

3.  Links between gut microbiome composition and fatty liver disease in a large population sample.

Authors:  Matti O Ruuskanen; Fredrik Åberg; Ville Männistö; Aki S Havulinna; Guillaume Méric; Yang Liu; Rohit Loomba; Yoshiki Vázquez-Baeza; Anupriya Tripathi; Liisa M Valsta; Michael Inouye; Pekka Jousilahti; Veikko Salomaa; Mohit Jain; Rob Knight; Leo Lahti; Teemu J Niiranen
Journal:  Gut Microbes       Date:  2021 Jan-Dec

4.  Chicory: Understanding the Effects and Effectors of This Functional Food.

Authors:  Céline L Pouille; Souad Ouaza; Elise Roels; Josette Behra; Melissa Tourret; Roland Molinié; Jean-Xavier Fontaine; David Mathiron; David Gagneul; Bernard Taminiau; Georges Daube; Rozenn Ravallec; Caroline Rambaud; Jean-Louis Hilbert; Benoit Cudennec; Anca Lucau-Danila
Journal:  Nutrients       Date:  2022-02-23       Impact factor: 5.717

Review 5.  PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease.

Authors:  Rosa Lombardi; Roberto Piciotti; Paola Dongiovanni; Marica Meroni; Silvia Fargion; Anna Ludovica Fracanzani
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

6.  Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis.

Authors:  Mujdat Zeybel; Muhammad Arif; Xiangyu Li; Ozlem Altay; Hong Yang; Mengnan Shi; Murat Akyildiz; Burcin Saglam; Mehmet Gokhan Gonenli; Buket Yigit; Burge Ulukan; Dilek Ural; Saeed Shoaie; Hasan Turkez; Jens Nielsen; Cheng Zhang; Mathias Uhlén; Jan Borén; Adil Mardinoglu
Journal:  Adv Sci (Weinh)       Date:  2022-02-07       Impact factor: 16.806

7.  Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.

Authors:  Flavia Noelia Mazzini; Frank Cook; John Gounarides; Sebastián Marciano; Leila Haddad; Ana Jesica Tamaroff; Paola Casciato; Adrián Narvaez; María Florencia Mascardi; Margarita Anders; Federico Orozco; Nicolás Quiróz; Marcelo Risk; Susana Gutt; Adrián Gadano; Celia Méndez García; Martin L Marro; Alberto Penas-Steinhardt; Julieta Trinks
Journal:  Metabolomics       Date:  2021-06-16       Impact factor: 4.290

Review 8.  Role of gut microbiota via the gut-liver-brain axis in digestive diseases.

Authors:  Jian-Hong Ding; Zhe Jin; Xiao-Xu Yang; Jun Lou; Wei-Xi Shan; Yan-Xia Hu; Qian Du; Qiu-Shi Liao; Rui Xie; Jing-Yu Xu
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

9.  Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients.

Authors:  Mujdat Zeybel; Ozlem Altay; Muhammad Arif; Xiangyu Li; Hong Yang; Claudia Fredolini; Murat Akyildiz; Burcin Saglam; Mehmet Gokhan Gonenli; Dilek Ural; Woonghee Kim; Jochen M Schwenk; Cheng Zhang; Saeed Shoaie; Jens Nielsen; Mathias Uhlén; Jan Borén; Adil Mardinoglu
Journal:  Mol Syst Biol       Date:  2021-10       Impact factor: 11.429

10.  The Intestinal Microbiome Predicts Weight Loss on a Calorie-Restricted Diet and Is Associated With Improved Hepatic Steatosis.

Authors:  Tien S Dong; Kayti Luu; Venu Lagishetty; Farzaneh Sedighian; Shih-Lung Woo; Benjamin W Dreskin; William Katzka; Candace Chang; Yi Zhou; Nerea Arias-Jayo; Julianne Yang; Aaron I Ahdoot; Jason Ye; Zhaoping Li; Joseph R Pisegna; Jonathan P Jacobs
Journal:  Front Nutr       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.